Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viatris Inc VTRS

Healthcare
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand... see more

Recent & Breaking News (NDAQ:VTRS)

Viatris to Report First Quarter 2024 Financial Results on May 9, 2024

PR Newswire 8 days ago

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

PR Newswire 10 days ago

Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada

Canada NewsWire 10 days ago

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl(TM) (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

GlobeNewswire April 1, 2024

Viatris Announces the Launch of RYZUMVl(TM) (Phentolamine Ophthalmic Solution) 0.75% in the United States

PR Newswire April 1, 2024

Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline

PR Newswire March 27, 2024

Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris

Business Wire March 11, 2024

Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

PR Newswire February 28, 2024

Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration

PR Newswire February 28, 2024

Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results

PR Newswire February 5, 2024

Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire December 21, 2023

Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer

PR Newswire December 15, 2023

Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders

PR Newswire December 15, 2023

Viatris Partners With Comfort Cases to Support Youth in U.S. Foster Care

Accesswire November 21, 2023

Viatris to Participate in the Jefferies London Healthcare Conference

PR Newswire November 14, 2023

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

PR Newswire November 13, 2023

Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]

PR Newswire November 7, 2023

Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance

PR Newswire October 30, 2023

Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row

Accesswire October 25, 2023

Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row

PR Newswire October 23, 2023